Is The COVID-19 Investor’s Portfolio Legit? [Nexus-9 Network]

Welcome to my review of Michael Robinson’s COVID-19 Investor’s Portfolio .

During the pandemic, if you have looking for an investment advisory service to help guide you through the volatility, you should consider Robinson’s Nexus-9 Network.

But before we get to the newsletter, the COVID-19 Investor’s Portfolio presentation concerns a company that is expected to bring to market a coronavirus vaccine.

If you have encountered the presentation and are wondering what to make of it, this honest review should furnish you with the details you need to decide whether the newsletter is worth signing up for.

Before I start…

If you’re tired of scams and want a real solution for making money online check out my no.1 recommendation.

It’s helped me earn over $300,000 in the last 12 months alone:

Go here to see my no.1 recommendation for making money online

(This is a 100% free training)

Is The COVID-19 Investor’s Portfolio Legit? [Nexus-9 Network] 3

The COVID-19 Investor’s Portfolio Review

RECOMMENDED: Go here to see my no.1 recommendation for making money online

Introduction to The COVID-19 Investor’s Portfolio

The COVID-19 Investor’s Portfolio presentation centers on a biotech company that’s working on a vaccine for the novel coronavirus. With health specialists worried about a second devastating wave of infections, pharmaceutical companies, biotechs, and other research institutions have been working tirelessly on a vaccine. 

Michael Robinson asserts that 70 firms (commercial) are currently working on a vaccine. However, he is singling one out as an unlikely frontrunner. 

The COVID-19 Investor’s Portfolio

The firms are competing because they know that whoever succeeds to bring one to market will not have a shortage of demand. As soon as a vaccine arrives, the firm behind it will rise exponentially. 

Michael is betting on one biotech company that he expects to lead the race. He thinks that if you invest in it, you may earn up to 3,000% in positive returns. 

RECOMMENDED: Go here to see my no.1 recommendation for making money online

Who Is the Creator of The COVID-19 Investor’s Portfolio?

Michael Robinson is a financial analyst who specializes in the technology sector. He is has worked in and around Silicon Valley for more than three decades (approximately 37 years). 

During that period, he has worked for several Silicon Valley venture capital firms and in the process, made the acquaintance of many high-profile industry insiders. 

Michael Robinson is a regular guest panelist of platforms like CNBC and Fox Business.

He is a published author. His book, Overdrawn: The Bailout of American Savings, discusses the problem of corporate greed and the consequences it has had on savings.

This is not the first time I am encountering Michael Robinson’s work. I have reviewed previous presentations of his, including $2.4 Billion Private Cannabis Deal, Cryogenic Blood, and The Next $52 Billion Startup.

RECOMMENDED: Go here to see my no.1 recommendation for making money online

How Does The COVID-19 Investor’s Portfolio Work?

Michael Robinson focuses on trendy fields in the tech industry, such as artificial intelligence, e-commerce, robotics and machine learning, social media, cloud computing, big data, 5G wireless, cybersecurity, and biotech. Collectively, he refers to these nine industries as Nexus-9 Network.

To gain access to The COVID-19 Investor’s Portfolio, you need to join the Nexus-9 Network. In doing so, Michael will always let you know when it’s the right time to buy or sell a stock. You will also gain access to Michael Robinson’s research and analysis. 

To start you off, he will send you guides on three companies that he thinks are going to take the lead in the race to make a coronavirus vaccine. 

  • The first pick on the list is a tiny company that is developing a COVID-19 vaccine. He expects this company to allow you to make 3,000% in returns.
  • The second pick is in the process of developing an oral version of the coronavirus vaccine and smart investments in this company’s stocks can offer you 2,000% gains.
  • The third one is also working on a COVID-19 vaccine that is getting tested on animals. It can offer you a 213% gain if you invest in it.

The Annual Subscription Price to the Nexus-9 Network: $1,950

RECOMMENDED: Go here to see my no.1 recommendation for making money online

Pros of The COVID-19 Investor’s Portfolio

  • It contains three biotech picks that can potentially offer you good returns on your investment.
  • The Nexus-9 Network regularly provides you with profit opportunities based on Michael Robinson’s research.

Cons of The COVID-19 Investor’s Portfolio

  • This investment advisory service isn’t available for free. You have to pay a subscription fee of $1950.

Is The COVID-19 Investor’s Portfolio Legit?

The COVID-19 Investor’s Portfolio is legit.

At a time when biotech companies are hard at work developing a vaccine for COVID-19, it makes sense that Michael Robinson is recommending that you invest in biotechs. He has crafted a strategy that, according to him, will earn you decent returns. 

That being said, should you expect to make 3,000% returns on a single stock riding the coronavirus hype? Probably not.

RECOMMENDED: Go here to see my no.1 recommendation for making money online

Verdict for The COVID-19 Investor’s Portfolio

If your portfolio has been decimated by the coronavirus-induced market volatility, you may be looking to invest in biotech companies due to a surge in interest in those companies as they develop a vaccine. While Michael Robinson claims to have a strategy in place behind the COVID-19 Investor’s Portfolio to help his readers bag those profits, it is not going to be a smooth ride. 

Some experts even think that there is not much money to be made even when a biotech company makes a breakthrough because all the potential gains may have already been priced in due to the hype.

As for the profit element, you should also be prepared to wait for a year or longer of testing and when the vaccine hits the market, the people running those companies — who most likely are ethical managers — may decide to not charge a premium for a vaccine needed to solve a public health crisis.

There are many ways to look at it but I think you should think twice about investing in biotech companies that are working on the COVID-19 vaccine.

However, the Nexus-9 Network may be worth a shot if you are looking to venture into tech investments under the guidance of someone who has been around the industry for decades.

Before you leave

If you’re tired of scams and want a real solution for making money online check out my no.1 recommendation.

It’s helped me earn over $300,000 in the last 12 months alone:

Go here to see my no.1 recommendation for making money online

(This is a 100% free training)

Is The COVID-19 Investor’s Portfolio Legit? [Nexus-9 Network] 3